EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cathepsins and SARS‐CoV‐2 infection: From pathogenic factors to potential therapeutic targets

Shuxuan Zhao, Muzhou Jiang, Hong Qing, Junjun Ni iD

British Journal of Pharmacology · 2023-10 · 180 (19) · 2455-2481

DOI: 10.1111/bph.16187 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 04.08.2023. Verfasst von Shuxuan Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, Beijing, China. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 133 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease‐19 (COVID‐19) is caused by severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2) infection. The COVID‐19 pandemic began in March 2020 and has wrought havoc on health and economic systems worldwide. Efficacious treatment for COVID‐19 is lacking: Only preventive measures as well as symptomatic and supportive care are available. Preclinical and clinical studies have indicated that lysosomal cathepsins might contribute to the pathogenesis and disease outcome of COVID‐19. Here, we discuss cutting‐edge evidence on the pathological roles of cathepsins in SARS‐CoV‐2 infection, host immune dysregulations, and the possible underlying mechanisms. Cathepsins are attractive drug targets because of their defined substrate‐binding pockets, which can be exploited as binding sites for pharmaceutical enzyme inhibitors. Accordingly, the potential modulatory strategies of cathepsin activity are discussed. These insights could shed light on the development of cathepsin‐based interventions for COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSARS-CoV-2CathepsinsVirulence FactorsPandemicsAntiviral Agents

Stichwörter der Autor:innen

COVID-19SARS-CoV-2cathepsincathepsin inhibitorsdrug discovery

Substanzen

CathepsinsVirulence FactorsAntiviral Agents

Autor:innen und Institutionen

  • Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, Beijing, China.
  • Department of Periodontics, Liaoning Provincial Key Laboratory of Oral Diseases, School and Hospital of Stomatology, China Medical University, Shenyang, China.

ORCID-Profile: Junjun Ni

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Zhao, S., Jiang, M., Qing, H., & Ni, J. (2023). Cathepsins and SARS‐CoV‐2 infection: From pathogenic factors to potential therapeutic targets. British Journal of Pharmacology, 180(19), 2455-2481. https://doi.org/10.1111/bph.16187

Vancouver

Zhao S, Jiang M, Qing H, Ni J. Cathepsins and SARS‐CoV‐2 infection: From pathogenic factors to potential therapeutic targets. British Journal of Pharmacology. 2023;180(19):2455-2481. doi:10.1111/bph.16187

BibTeX
@article{Zhao2023,
  author = {Zhao, Shuxuan and Jiang, Muzhou and Qing, Hong and Ni, Junjun},
  title = {Cathepsins and SARS‐CoV‐2 infection: From pathogenic factors to potential therapeutic targets},
  journal = {British Journal of Pharmacology},
  year = {2023},
  volume = {180},
  number = {19},
  pages = {2455--2481},
  doi = {10.1111/bph.16187}
}
Kostenlos starten →